Grantham, Mayo, Van Otterloo & Co (GMO)’s Amneal Pharmaceuticals AMRX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,100	Closed	-$71.6K	–	579
2023 Q2	$71.6K	Hold	23,100	–	–	﹤0.01%	664
2023 Q1	$32.1K	Buy	+23,100	New	+$46K	﹤0.01%	690
2022 Q3	–	Sell	-146,500	Closed	-$466K	–	713
2022 Q2	$466K	Hold	146,500	–	–	﹤0.01%	621
2022 Q1	$611K	Buy	146,500 +122,100	+500%	+$541K	﹤0.01%	579
2021 Q4	$117K	Buy	+24,400	New	+$122K	﹤0.01%	672
2021 Q1	–	Sell	-154,700	Closed	-$707K	–	836
2020 Q4	$707K	Sell	154,700 -63,400	-29%	-$281K	﹤0.01%	629
2020 Q3	$846K	Buy	+218,100	New	+$933K	0.01%	547

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s AMRX Position: Q3 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Amneal Pharmaceuticals (AMRX) in Q3 2023, closing a stake of 23,100 shares — an estimated $71.6K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in AMRX in Q3 2020 and held it in 7 quarters. The position peaked at $846K in Q3 2020. 144 funds tracked by Wall St. Rank hold AMRX as of Q3 2023.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Amneal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 23,100 Amneal Pharmaceuticals shares in Q3 2023, an estimated $71.6K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Amneal Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Amneal Pharmaceuticals position peaked at $846K in Q3 2020.
144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2023, filed 13 Nov 2023.